tumor-pulsed dendritic cells

Tumor-pulsed dendritic cells are a form of personalized cell-based immunotherapy in which autologous (patient-derived) dendritic cells are cultured and then "pulsed" or loaded with antigens derived from the patient's own tumor—typically as whole tumor lysate, killed/inactivated tumor cells, or specific peptides. These antigen-loaded dendritic cells are then administered back to the patient as a therapeutic vaccine. The goal is to stimulate a robust and specific anti-tumor immune response by presenting a broad array of relevant tumor antigens to T lymphocytes, thereby priming cytotoxic T cell responses against cancer. This approach has been tested in various cancers including melanoma and solid tumors, often in early-phase clinical trials[2][3][4]. Mechanistically, these vaccines rely on the potent antigen-presenting capacity of mature dendritic cells to activate both CD8+ cytotoxic T lymphocytes and CD4+ helper T cells for targeted anti-tumor immunity[2][3]. Tumor-pulsed DC therapy is typically considered an investigational immunotherapy.

Other names

dendritic cell vaccine pulsed with tumor antigenstumor lysate-pulsed dendritic cellsautologous tumor-pulsed DCs